Clinicopathologic risk factor distributions for MLH1 promoter region methylation in CIMP-positive tumors

A. Joan Levine, Amanda I. Phipps, John A. Baron, Daniel D. Buchanan, Dennis J. Ahnen, Stacey A. Cohen, Noralane M. Lindor, Polly A. Newcomb, Christophe Rosty, Robert W. Haile, Peter W. Laird, Daniel J. Weisenberger

Research output: Contribution to journalArticlepeer-review

16 Scopus citations

Abstract

Background: The CpG island methylator phenotype (CIMP) is a major molecular pathway in colorectal cancer. Approximately 25% to 60% of CIMP tumors are microsatellite unstable (MSI-H) due to DNA hypermethylation of the MLH1 gene promoter. Our aim was to determine if the distributions of clinicopathologic factors in CIMP-positive tumors with MLH1 DNA methylation differed from those in CIMP-positive tumors without DNA methylation of MLH1. Methods: We assessed the associations between age, sex, tumor-site, MSI status BRAF and KRAS mutations, and family colorectal cancer history with MLH1 methylation status in a large population-based sample of CIMP-positive colorectal cancers defined by a 5-marker panel using unconditional logistic regression to assess the odds of MLH1 methylation by study variables. Results: Subjects with CIMP-positive tumors without MLH1 methylation were significantly younger, more likely to be male, and more likely to have distal colon or rectal primaries and the MSI-L phenotype. CIMP-positive MLH1-unmethylated tumors were significantly less likely than CIMP-positive MLH1-methylated tumors to harbor a BRAF V600E mutation and significantly more likely to harbor a KRAS mutation. MLH1 methylation was associated with significantly better overall survival (HR, 0.50; 95% confidence interval, 0.31-0.82). Conclusions: These data suggest that MLH1 methylation in CIMP-positive tumors is not a completely random event and implies that there are environmental or genetic determinants that modify the probability that MLH1 will become methylated during CIMP pathogenesis. Impact: MLH1 DNA methylation status should be taken into account in etiologic studies.

Original languageEnglish (US)
Pages (from-to)68-75
Number of pages8
JournalCancer Epidemiology Biomarkers and Prevention
Volume25
Issue number1
DOIs
StatePublished - Jan 2016

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Fingerprint Dive into the research topics of 'Clinicopathologic risk factor distributions for MLH1 promoter region methylation in CIMP-positive tumors'. Together they form a unique fingerprint.

Cite this